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Abstract
Background: Participation in cognitive stimulation therapy (CST) may reduce the rate of cognitive decline in
people with Alzheimer’s disease (AD), however it is unclear if the training of carers to deliver activities is sufficient
to improve the clinical outcome of patients. The Promoting Healthy Ageing with Cognitive Exercise for Alzheimer’s
Disease (PACE-AD) study has been designed to determine if change in cognitive function over a six month period
can be achieved with participation in cognitive stimulating activities when the intervention is delivered to carers
only as opposed to carers and patients.
Methods/Design: The study will aim to recruit 128 community-dwelling men and women with probable AD
according to NINCDS-ADRDS criteria. Participants will be randomly allocated to one of two cognitive activity
treatment groups: (1) Participants with mild AD and their companions together (2) Companions of participants
with mild AD alone. The intervention will consist of a twelve-week program of cognitive stimulation. Seven weeks
of the program will involve 90-minute group sessions delivered once per week while the remaining weeks of the
program will involve structured home based activities with telephone support. The primary outcome measure of
the study is the change from baseline in the total score on the Alzheimer Disease Assessment Scale-Cognitive
(ADAS-COG). Secondary outcomes of interest include changes in health related quality of life, mood, memory,
language, executive functions, independent living abilities and psychiatric symptoms for participants with mild AD.
Changes in companion quality of life, mood, and general health will also be monitored. Primary endpoints will be
collected 13 and 26 weeks after the baseline assessment.
Discussion: The proposed project will provide evidence as to whether CST for people with AD and their
companions is more beneficial than when used for companions alone. Outcomes sought include a reduction of
further cognitive decline and improved quality of life amongst older adults with mild AD. We anticipate that the
results of this study will have implications for the development of cost-effective evidence-based best practice to
treat people with mild AD.
Trial registrationACTRN12610000653066
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Cognition-focused interventions are becoming increas-
ingly popular techniques for older adult populations.
These interventions are typically grouped into one of
three categories - cognitive training, cognitive rehabilita-
tion and cognitive stimulation. Interventions may vary
in terms of the degree to which the program is indivi-
dualised, the content of the activity and the nature of
the facilitation (e.g. one-to-one, group, computer based)
(see [1] for a review).
Cognitive stimulation therapy (CST) has been recom-
mended as the treatment of choice for individuals in the
early stages of dementia (Mini Mental State Examination -
MMSE, score ≥ 20) [2]. This type of intervention empha-
sises the benefits of group activities which, dependent on
the target population, can range from education, discus-
sion and debate, and problem solving to reality orienta-
tion, reminiscence and validation therapy. In a multi-
centred randomised controlled trial (RCT), Spector and
colleagues [3] allocated 201 participants with dementia to
either a CST group or a no treatment control. People in
the intervention demonstrat e di m p r o v e dc o g n i t i v ea n d
quality of life scores. A Cochrane review of reminiscence
therapy concluded that whilst there was a need for more
rigorous trials, there were promising indications that this
form of intervention was of potential benefit to patients
and their carers [4]. The cost effectiveness of CST has also
been established [5] and manuals operationalised [6].
CST has traditionally been implemented in group set-
tings such as day centres and residential facilities and
co-ordinated by trained facilitators. Some interventions
have also adopted multi-modal programs targeting cog-
nition and well being in the patient with dementia and
addressing the coping abilities and needs of the family
member/care-giver with positive results (e.g. [7]). How-
ever there is a paucity of research that has utilised cog-
nitive stimulation techniques in a manner easily adopted
for the home environment and implemented by the
carer/family member.
Quayhagen and Quayhagen [8] had spousal caregivers
apply cognitive stimulation techniques and found that
improvements in memory, as well as additional aspects
of cognition, could be achieved, with a home-based pro-
gram. This study, however, was limited to spouses and a
research team modelled the programme in the home of
the dyad. For those patients who are widowed or single,
access to a carer or companion may be limited to less
contact hours. The feasibility of having instructors/team
members provide one-to-one instruction may also
restrict the availability of this type of facilitation.
We have designed a single-blind, randomized trial of
an intervention drawing on principles of cognitive sti-
mulation. The activities and intervention were selected
with regard to suitability for older adults with mild Alz-
heimer’s disease (AD) and designed in a manner that
could be readily adapted for use in the home environ-
ment and implemented by a companion. The study aims
to determine if a program of cognitive activity (CA) that
includes both people with AD living in the community
and a companion has better cognitive outcomes over six
months for participants with dementia than a CA pro-
gram delivered to companions only. Secondary out-
comes for this trial include the quality of life and well
being of people with AD and their companions.
Methods/Design
Background
The Promoting Healthy Ageing with Cognitive Exercise
for the treatment of mild Alzheimer’s Disease (PACE-
AD) study is a randomised clinical trial that commenced
recruitment of participants in October 2009.
In 2007, our group developed a cognitive activity
intervention program which was well received by older
adults with mild cognitive impairment [9]. In early 2009,
this program was modified for its suitability for partici-
pants with mild AD. Nine relatives of individuals with
mild AD were invited to attend a morning education
and activity session regarding the proposed study. Feed-
back from the relatives regarding the nature of the
study was overwhelmingly positive, though the length of
the proposed sessions, coupled with the complexity of
the program content, were areas identified as requiring
further consideration. After collating the verbal and
written feedback, additional minor modifications were
made to the study protocol and recruitment began.
Study Design and Setting
PACE-AD is a six-month, single blind randomised trial
of a CA intervention delivered to older adults with mild
AD and companions compared with companions alone.
Ethics
The Human Research Ethics Committees of Royal Perth
Hospital (RPH), Mercy Hospital and Bentley Hospital
have approved the study protocol and procedures, and
the study is being conducted according to the Declara-
tion of Helsinki.
Recruitment and Selection of participants
Recruitment for this trial is currently ongoing. Partici-
pants are community dwelling volunteers, recruited
mainly from local memory clinics. Potentially suitable
participants are approached via mail and receive a follow
up telephone call. Interested volunteers are screened
with a semi-structured telephone interview and invited
to visit the Mercy Hospital for a more detailed screening
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informed consent.
Inclusion and Exclusion Criteria
The defining feature of participants included in the
PACE-AD study is a diagnosis of Alzheimer’sd i s e a s e
(probable or possible) according to the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disor-
ders Association (NINCDS-ADRDA) Alzheimer’sC r i -
teria. Participants need to have a Mini Mental State
Examination (MMSE) score between 18-26 inclusive (i.
e., mild severity), at the time of screening and be fluent
in written and spoken English.
Mild AD participants with a prevalent psychiatric dis-
order (e.g. depressive episode), current history of hazar-
dous or harmful alcohol consumption (Alcohol Use
Disorders Identification Test - AUDIT - score ≥15 [10]),
or who do not have an available companion are
excluded. Those individuals with a current medical con-
dition preventing participation in the study tasks (such
as severe sensory impairment) or associated with
reduced survival over a six-month period (e.g. advanced
cancer) are also excluded.
Telephone Interview
Volunteers are initially screened via a telephone inter-
view to ascertain suitability for the study. Those without
a suitable companion (someone who spends at least ten
hours per week with the person, including time at their
home) are immediately excluded. All individuals are
asked about their general health (past and current), edu-
cation, English literacy skills and current alcohol and
cigarette consumption. Telephone interviews range from
10 to 20 minutes in length and those meeting provi-
sional inclusion criteria are invited to a face-to-face
assessment (clinic screen).
Clinic Screen
After obtaining written consent from volunteers with
mild AD and their companions each person’s eligibility
for the study is established according to the following
criteria:
Mild AD ￿ Mini Mental State Examination score ran-
ging between 18-26 inclusive [11]
￿ Patient Health Questionnaire (PHQ-9) score <15
[12]
For the companion of the volunteer with mild AD ￿
MMSE total score of 26 or above [11]
￿ PHQ-9 score <15 [12]
The MMSE [11] is a brief test of mental status and
cognitive function commonly used to screen for demen-
tia and to monitor cognitive decline. It produces a total
score that can range from 0 to 30. Scores lower than 24
are reliably associated with the diagnosis of dementia or
other organic mental disorders. The present study also
used the MMSE to exclude companions with cognitive
impairment. The PHQ-9 [12] is a widely used scale to
establish the presence of clinically significant depression
amongst community-dwelling adults. Scores range from
0 to 27, with scores of 15 or greater indicative of clini-
cally significant depression.
In addition to the cognitive and mood screen, a self-
reported medical history questionnaire is completed by
each individual, which includes details regarding their
medication usage. This information is also collected at
the final assessment. The screening assessment of both
volunteers takes approximately 30 minutes to complete
and any pertinent clinical information is reported to the
relevant treating physician with the consent of the study
participant. If both volunteers meet criteria for the study,
they proceed to undertake the baseline assessment.
Outcome Measures and Assessment Procedures
Baseline and Follow-up Assessments
Baseline assessments are completed immediately after
the clinic screen, 1-2 weeks prior to the first interven-
tion session and randomisation. Post-intervention
assessments are undertaken within two weeks of pro-
gram completion and the final assessment is completed
2 6w e e k sa f t e rt h eb a s e l i n ea s s e s s m e n t( s e eF i g u r e1 ) .
All assessments take between 90 to 120 minutes to
complete (including the provision of short breaks) and
consist of the following series of tests and question-
naires (see also Table 1).
Receive invitation letter 
 
Complete telephone screening interview 
 
Attend baseline visit at Mercy Hospital, Mt Lawley 
 
Random assignment to either: 
 
GROUP 1    GROUP 2 
Weeks 1-6    Weeks 1-6 
Person with AD & Companion 
 
Attend weekly CA sessions 
Complete weekly home activities 
 
Person with AD 
Completes  home 
activities 
Companion Attends 
weekly CA sessions 
Weeks 7-11  Weeks 7-11 
Complete weekly home activities    Complete weekly home activities 
Week 12    Week 12 
Attend final CA session    Companion attends final CA session 
Complete follow-up assessment 
Within 1 month of end of program 
  Complete follow-up assessment 
Within 1 month of end of program 
     
Complete final  
follow-up visit 
26 weeks after baseline 
  Complete final  
follow-up visit 
26 weeks after baseline 
Figure 1 Baseline assessment.
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Alzheimer Disease Assessment Scale-Cognitive (ADAS-
COG) [13] is a frequently used measure of global cogni-
tive functioning and assesses cognitive domains includ-
ing orientation, memory, language, and praxis; common
areas of impairment present in AD. It provides sub-scale
scores as well as a global score out of 70, with higher
scores indicating lower levels of cognitive functioning.
A four-point change on the ADAS-COG over a six
month period is considered a clinically relevant differ-
ence [14,15].
Secondary Outcome Measures
Measures completed by participants with mild AD
The Rivermead Behavioural Memory Test-Third Edition
(RBMT-3) [16] comprises a series of memory tasks ana-
logous to those faced in everyday situations. Sensitive to
changes in memory functioning over time and well vali-
dated with patient groups [16], a parallel version also
reduces the confounds of practice effects. Three subtests
from the RBMT-3 are performed with mild AD partici-
pants at all assessment time points, with the parallel ver-
sion administered at the post intervention assessment.
The Tower of London (ToL) [17] consists of ten pro-
blems of increasing difficulty designed to assess execu-
tive planning abilities. The participant is required to
manipulate three coloured beads across three pegs on a
wooden board to mirror the examiner’s board. Partici-
pants are instructed to solve the problem in as few
moves as possible while adhering to two specific rules,
within a two minute time limit. In the current trial this
test is administered with minor modifications, in order
to minimise frustration for participants with mild AD.
The Controlled Word Association Test (COWAT)
[18] requires the participant to generate as many words
as possible with a given letter of the alphabet, within a
one-minute time period, excluding proper nouns and
the same word with a different suffix. This test is used
as an indicator of executive functioning for participants
with mild AD.
Measures completed by participants with mild AD
and their companions We use the MMSE total score
and the PHQ-9 total score, as previously described, to
monitor changes in cognition and mood of all partici-
pants throughout the trial.
DEMQOL-version 4 [19] is a 28-item self-reported,
interviewer administered questionnaire assessing partici-
pants’ perceptions of their health related quality of life in
the past week. It assesses five domains: daily activities/self
care, health and well-being, cognitive functioning, social
relationships, and self-concept. The DEMQOL has been
demonstrated to show high reliability (internal consis-
tency and test-retest) and moderate validity in people
with mild to moderate dementia. In this trial, participants
with mild AD are given the questions verbally with the
aid of visual response options. Companions’ quality of life
is also assessed with this measure.
Modified Short Form of the Informant Questionnaire
on Cognitive Decline in the Elderly (Short-Form IQ
Code) [20] is an informant based, brief cognitive screen-
ing questionnaire for individuals with dementia. It
assesses an individual’sc o g n i t i v ea b i l i t i e sa st h e ya p p l y
to everyday situations and consists of 16 items. The ori-
ginal version asks the informant to judge the extent to
which the patient’s level of functioning has changed in
the past ten years. Subsequent versions have used differ-
ent time frames to allow for informants who might not
have known the patient for very long. In this trial only
AD participants’ current level of functioning will be
assessed, to allow direct comparison at follow-up testing.
Measures completed by companions The Lawton
Instrumental Activities of Daily Living (IADL) [21] scale
is an informant based questionnaire which assesses the
patient’s current ability to perform eight independent
activities of daily living. These include using the tele-
phone, shopping, food preparation, housekeeping, laun-
dry, mode of transportation, taking medications and
handling finances.
The Neuropsychiatric Inventory Questionnaire (NPI-
Q) [22] is a brief screening instrument assessing the
frequency and severity of twelve neuropsychiatric beha-
vioural disturbances common in dementia. The compa-
nion is asked to rate the presence, change and severity
Table 1 Outline of the primary and secondary outcome
measures used in the PACE-AD trial
Assessment Tool Participant with mild AD Companion
ADAS-COG X
RBMT-3 X
ToL X
COWAT X
MMSE X X
PHQ-9 X X
DEMQOL-version 4 X X
Short-Form IQ CODE X X
IADL X
NPI-Q X
AUDIT X
SF-12 X
The X indicates who completed the respective assessments (participant with
mild AD or companion). All measures were given at baseline, 13 and 26 weeks.
ADAS-COG = Alzheimer Disease Assessment Scale-Cognitive; RBMT-3 =
Rivermead Behavioural Memory Test-Third Edition; ToL = Tower of London;
COWAT = Controlled Oral Word Association Test; MMSE = Mini Mental State
Examination; PHQ-9 = Patient Health Questionnaire - Nine Item; Short-Form IQ
CODE = Modified Short Form of the Informant Questionnaire on Cognitive
Decline in the Elderly; IADL = The Lawton Instrumental Activities of Daily
Living; NPI-Q = The Neuropsychiatric Inventory Questionnaire; AUDIT = World
Health Organisation’s Alcohol Use Disorders Identification Test; SF-12 = Short-
Form 12-Item Health Survey.
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with associated caregiver distress. The NPI-Q is consid-
ered to be a reliable and valid tool for assessing psycho-
pathology in dementia patients and is sensitive to
treatment effects.
The World Health Organisation’s Alcohol Use Disor-
ders Identification Test (AUDIT) [10] is used to screen
for risky, hazardous or harmful drinking. There are 10
items and supplementary questions, with questions
scored on a scale of 0 to 4. Scores of 16 or above sug-
gest “high-risk” or “harmful level” of drinking behaviour.
This questionnaire is monitoring the companion’sa l c o -
hol usage throughout the trial.
Short-Form 12-Item Health Survey (SF-12) [23] is a self-
report questionnaire consisting of twelve questions from
the SF-36 Health Survey [24] and assesses an individual’s
perception of their general physical/health functioning,
bodily pain, vitality, social functioning, general mental
health, psychological wellbeing, and role limitations due to
physical or emotional issues. This questionnaire is used to
monitor change in the companion’s mental and physical
components of quality of life throughout the trial.
DNA Collection
Participants with mild AD are asked to provide a saliva
sample for the extraction of DNA to assess the influence
of common genetic polymorphisms (e.g., apolipoprotein
E4 genotype) on the outcomes of the study. The sam-
ples are collected and processed by the Department of
Clinical Pathology and Biochemistry at the RPH and
stored at -80°C. All material is batched and will only be
processed at the end of the trial.
Intervention
Following the baseline assessment, dyads (person with
mild AD and companion) are randomised to one of two
intervention groups. The intervention consists of a
twelve-week CA program. Sessions are run by facilita-
tors experienced in conducting research with older
adults. The two groups are exposed to the same length
of intervention, social interaction and contact with the
program facilitators. The program was developed by a
qualified Neuropsychologist (MV) and a manual pro-
duced. All of the sessions are delivered in a structured
way for consistency, and audio-taped for subsequent
fidelity assessment.
Research assistants (RAs) blinded to group allocation
conduct all assessments. RAs are provided with strict
instructions to avoid any potential opportunity for dis-
closure regarding intervention participation. Following
completion of the trial, RAs undertaking data collection
will be asked to identify the group membership of partici-
pants, to determine the effectiveness of the blinding pro-
cedures that were put in place for this project. A brief
summary of each intervention group is provided below.
Participants with mild AD and their companions
(Group 1): Each group consists of a maximum of five
dyads taking part in 90-minute sessions once a week
for seven weeks. Session One introduces the nature of
the program and develops familiarity within the group,
with personal introductions and sharing of background
information and experiences. Sessions Two to Six
focus on defining attention, processing speed, memory,
language and executive functions. These sessions out-
line how these cognitive abilities are affected in AD
and provide participants with strategies and techniques
for managing declining capacity in each of these
domains. Regular opportunity for supervised practice
of such techniques and examples of activities to
strengthen abilities occurs in all sessions. Dyads are
also provided with an hour of home activities, to rein-
force material learnt in the sessions. Sessions Seven to
Eleven are completed by the participant with mild AD
and their companion together in their own environ-
ment. Participants are provided with a workbook con-
taining instructions and examples, along with phone
calls from the facilitator once per week to address any
questions and to monitor task completion. The final
session (Session 12) offers an overview and discusses
strategies to maximise participation.
Companions of participants with mild AD alone
(Group 2): This group consists of a maximum of five
companions presented with the same session informa-
tion and materials as Group 1. The only difference is
that the companions attend the sessions with other
companions, and are instructed to convey what is learnt
during the sessions to the participant with mild AD dur-
ing their home activities.
Randomisation
Randomisation is performed according to a random list
of numbers generated by computer and undertaken in
random blocks of 8 or 10 with no more than five dyads
allocated to each group. The allocation list is handled by
an independent investigator (OPA) who has no contact
with study participants and is not involved in the super-
vision of staff responsible for the collection of data. The
allocation table is then passed on to the facilitator run-
ning the intervention, who invites eligible participants to
join the relevant groups. RAs undertaking the follow-up
assessments remain blinded to group allocation.
Sample Size and Power Calculation
This trial aims to recruit 128 participants with mild AD
and their carers, with 64 patients being allocated to each
study group. A study of this size will have 80% power to
detect between group differences on the ADAS-COG
associated with moderate effect size (Cohen’sd=0 . 5 )
and alpha of 5%.
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Changes in the ADAS-COG score from baseline are the
primary outcome of interest in the study. We will model
these changes at 2 time points: 13 (immediately after the
intervention comes to an end) and 26 weeks. We will
use mixed effects models to analyse the data. This
approach will enable us to take into account the cogni-
tive performance of participants at baseline, as well as
the intra-person correlation generated from repeated
measures. Intention-to-treat (ITT) analyses will be based
on the use of imputation by chain equations (ICE),
which will precede the use of the mixed-effects model.
The ITT will be the primary analysis of the study.
Discussion
Cognition-focussed interventions are increasingly being
adopted for the treatment of cognitive decline in older
adults, with CST recently recommended as the treat-
ment of choice for individuals with mild dementia [2].
However, the efficacy, sustainability of effect, and cost-
effectiveness of involving and training a carer/compa-
nion to deliver cognitive tasks, and the degree to which
cognitive changes can be maintained over time using
this form of delivery, is yet to be established.
This trial has been designed according to CONSORT
guidelines and has been structured to enable its repro-
duction in both research and clinical settings. We expect
to complete recruitment by December 2011 and antici-
pate that the results of this study will have implications
for health care policy and resourcing and facilitate
improvements in the management of people with mild
AD. The results of this study will enable us to deter-
mine, for the first time, if a CA intervention delivered to
companions alone is as effective at promoting changes
in cognitive function as an intervention involving both
the person with dementia and his/her companion. These
results will have important implications for the design of
sustainable cost-effective health services for people with
mild AD.
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